Anakinra, an IL-1β receptor antagonist, has been tested in various inflammatory conditions [82], and although preclinical studies in APP/PS1 AD mouse models show it reduces IL-1β signaling [83], specific clinical trials targeting mild cognitive impairment or AD are limited, necessitating further research to determine its efficacy in this context. This evidence concerns the gene IL1B and Alzheimer disease.